Your browser doesn't support javascript.
loading
Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet, Guillaume; Paillard, Marie-Justine; Maurina, Tristan; Vernerey, Dewi; Nguyen Tan Hon, Thierry; Almotlak, Hamadi; Stein, Ulrich; Calcagno, Fabien; Berthod, Diane; Robert, Elise; Meurisse, Aurelia; Thiery-Vuillemin, Antoine.
Affiliation
  • Mouillet G; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France. gmouillet@chu-besancon.fr.
  • Paillard MJ; Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besancon, France. gmouillet@chu-besancon.fr.
  • Maurina T; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, 25000, Besancon, France. gmouillet@chu-besancon.fr.
  • Vernerey D; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Nguyen Tan Hon T; Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Almotlak H; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Stein U; Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Calcagno F; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, 25000, Besancon, France.
  • Berthod D; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Robert E; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Meurisse A; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France.
  • Thiery-Vuillemin A; Department of Medical Oncology, University Hospital of Besançon, 25000, Besancon, France.
Trials ; 19(1): 221, 2018 Apr 12.
Article in En | MEDLINE | ID: mdl-29650037
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Protein Kinase Inhibitors / Sunitinib / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Guideline / Observational_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2018 Type: Article Affiliation country: France
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Protein Kinase Inhibitors / Sunitinib / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Guideline / Observational_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2018 Type: Article Affiliation country: France